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Predictors of Change in Bodily Pain in Early
Rheumatoid Arthritis: An Inception Cohort Study
DANIEL F. MCWILLIAMS,1 WEIYA ZHANG,1 JOSEPHINE S. MANSELL,1 PATRICK D. W. KIELY,2
ADAM YOUNG,3 AND DAVID A. WALSH4
Objective. To investigate possible predictors for lack of pain improvement after 1 year of treatment for early rheumatoid
arthritis (RA).
Methods. The Early Rheumatoid Arthritis Network (ERAN) database was used for analysis of baseline and 1-year pain
data. The ERAN is a hospital-based inception cohort of 1,189 people. Short Form 36 questionnaire bodily pain scores were
used to calculate change in pain at 1 year as the outcome. The proportion of the Disease Activity Score in 28 joints
(DAS28) attributable to patient-reported components (joint tenderness and visual analog scale score; DAS28-P) at baseline
was derived as a predictor. Predictors of less improvement in pain were investigated using adjusted odds ratios (ORadj)
generated by logistic regression, adjusting for 14 additional clinical and demographic covariates.
Results. Greater pain at baseline was associated with sex, high DAS28, worse mental health, and smoking. Most patients
with early RA reported incomplete improvement in bodily pain after 1 year. The DAS28-P index did not signiﬁcantly
change in the patients whose disease remained active. Less improvement in pain was predicted by female sex (ORadj 3.41,
95% conﬁdence interval [95% CI] 1.35–8.64) and a high DAS28-P index at baseline (ORadj for tertiles 2.09, 95% CI
1.24–3.55). Other conventional RA risk factors did not predict pain changes.
Conclusion. The factors most likely to predict less improvement in pain in early RA are female sex and a high DAS28-P
index. A high DAS28-P index may reﬂect greater contributions of noninﬂammatory factors, such as central sensitization,
to pain. Strategies in addition to inﬂammatory disease suppression may be required to adequately treat pain.
INTRODUCTION
The progress of rheumatoid arthritis (RA) is variable, and
despite the potential for severe disabling disease, many
patients will enter remission. Indeed, remission is becom-
ing more common (1) and achieving it quickly may im-
prove long-term outcomes (2). Recent clinical trials show
success in treating early RA aggressively (3), and also
when treatment choice is explicitly driven by regular ex-
aminations for disease activity (4).
The Disease Activity Score in 28 joints (DAS28) is com-
monly used to inform treatment decisions (5). The DAS28
is a composite score calculated from 28 tender joint counts
(TJCs), 28 swollen joint counts (SJCs), acute-phase re-
sponse (often the erythrocyte sedimentation rate [ESR]),
and a visual analog scale (VAS) of the patient’s self-re-
ported disease activity (general health [GH]) (6,7). Of these
factors, swollen joints and acute-phase response are deter-
mined by the assessor, whereas the VAS and tender joints
are reported by the patient, the latter in response to pres-
sure applied to the joint (8).
High DAS28 scores inﬂuence the choice of treatments of
early RA, and it is therefore important to understand the
relationship between DAS28 and inﬂammatory disease ac-
tivity, as well as potential effects of confounding factors.
Although self-reported disease activity and tenderness on
palpation increase alongside inﬂammatory disease activ-
ity, they may also be increased by changes in pain pro-
cessing such as central sensitization or by comorbidities.
Patients without RA who have ﬁbromyalgia or central
sensitization report high disease activity and tenderness,
generating high DAS28 scores despite low SJC and acute-
phase response that may be comparable to those of people
with active RA (9). Evidence of central sensitization and
joint inﬂammation may coincide, thereby confounding in-
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terpretation of the DAS28 in people with RA (10). People
with concurrent RA and ﬁbromyalgia report increased
pain (11) and show higher DAS28 scores (12) than those
with RA alone, perhaps indicating that central sensitiza-
tion or painful comorbidity inﬂuences the scoring.
Opinions differ as to whether ﬁbromyalgia should be
seen as a comorbidity in RA, or whether the clinical fea-
tures of ﬁbromyalgia represent changes in pain processing
associated with the arthritis. Seeing ﬁbromyalgia as a co-
morbidity suggests potential for treatments directed at
mechanisms other than joint inﬂammation in a subgroup
of patients. The extent to which pain processing is aber-
rant in RA may, however, occur across a continuum. Ap-
plication of ﬁbromyalgia classiﬁcation criteria in RA may
identify a subgroup of patients with the most abnormal
pain processing (13), but also may conceal a larger number
of patients in whom similar pain mechanisms make an
important contribution to their symptoms. In clinical prac-
tice, the DAS28 is often interpreted with regard to the
contribution of TJC and GH to the total score, based on
individual clinical judgment rather than standardized or
quantiﬁable criteria. We propose that a derived measure
for the contribution of these patient-reported components
to DAS28, measured here as the DAS28-P index, may be a
convenient and useful index of noninﬂammatory pain
mechanisms in RA.
Pain is often the most bothersome symptom of RA (14),
but epidemiologic risk factors for worse pain in RA have
been researched less thoroughly than outcomes such as
disease activity and radiologic damage. Pain is associated
with high disease activity (15) and can be reduced by early
effective treatment of inﬂammatory disease (16). Female
sex (15,17) may be related to worse pain over time, and
psychological factors inﬂuence pain reporting in RA
(15,18). Radiographic changes may be linked to future pain
in people with RA (15). Furthermore, changes in pain
processing through peripheral and/or central sensitization
may contribute to pain in RA (10,19,20).
The aims of this study were to determine if well-known
RA risk factors are associated with pain changes during the
ﬁrst year after presentation with RA, and also if the con-
tribution of patient-reported components to the DAS28 at
baseline predicts pain outcome. We used data from people
recruited to the Early Rheumatoid Arthritis Network
(ERAN) (21,22), an inception cohort study of patients with
newly diagnosed RA receiving standard care.
PATIENTS AND METHODS
Patients. The ERAN inception cohort study (21,22) re-
cruits from 22 outpatient centers in the UK and Ireland
(22,23). Recruitment began in April 2002, and still contin-
ues with followup. Prospectively collected data used in
this study were retrieved during winter 2010, and in-
cluded all patients who had attended the relevant clinics
and provided appropriate data. Previously reported data
from the ERAN include examinations of the patterns of
care and disease outcomes (24,25), validation of work
questionnaires (26,27), and factors inﬂuencing choice of
therapy (5). Patients are recruited to the ERAN following a
physician diagnosis of RA. ERAN centers monitor and
treat patients according to local practice, without require-
ment to follow any particular treatment protocol. Most of
the patients recruited during this period were treated ini-
tially with sulfasalazine or methotrexate as monotherapy
(5). At the time of this study, data from 1,189 patients were
available for analysis. The study was approved by the
Trent Research Ethics Committee (ref. 01/4/047) and all
participants gave signed informed consent in line with the
Declaration of Helsinki.
Data collection. Data collected prospectively at baseline
and at 1-year followup were used in this study. A clinical
examination and interview were performed at each visit
that were used to derive the DAS28-ESR, determine the
number of 1987 American College of Rheumatology (ACR)
RA diagnostic criteria that were fulﬁlled (28), and record
extraarticular disease manifestations or comorbidities
(coded as International Statistical Classiﬁcation of Dis-
eases and Related Health Problems, Tenth Revision chap-
ters on clinical record forms and supplemented by free
text). The presence of erosions was documented from ra-
diographs of the hands and feet that were taken for clinical
reasons. Demographic and clinical data were obtained
from case notes and a clinical interview and participants
were invited to complete the Short Form 36 (SF-36) ques-
tionnaire (29) and the Health Assessment Questionnaire
(HAQ) (30). Results of clinical tests for ESR and rheuma-
toid factor (RF) were obtained from the clinical record.
Seropositive individuals were those classiﬁed as positive
for RF or antibodies to citrullinated peptide. Results re-
ported as negative or weakly positive for RF according to
local reference ranges were classiﬁed as seronegative.
All observations were recorded and stored at the outpa-
tient centers and were also forwarded to the central data-
base. The veriﬁcation of local data was performed at visits
by the study coordinator (5). All assessments were timed
to coincide with clinical visits, such that 1-year followup
data in this report represent data collected 9–18 months
after baseline assessment (median 370 [interquartile range
(IQR) 350–408] days after baseline).
SF-36 subscales. The SF-36 Health Survey for patient-
based assessment of quality of life was used to evaluate
aspects of health that are frequently affected by disease
(29). The SF-36 is well accepted for assessing quality of life
in a number of disease populations, including RA (31,32).
Signiﬁcance & Innovations
● A derived patient-reported outcome measure for
the proportion of the Disease Activity Score in 28
joints (DAS28) contributed by tender joint count
and general health (DAS28-P) may help identify
noninﬂammatory inﬂuences on pain.
● A high DAS28-P at baseline predicts less improve-
ment in pain at 1 year in patients with rheumatoid
arthritis, despite traditional disease-modifying
therapy.
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We used the SF-36 bodily pain score as a measure of pain
in people with early RA. For every subscale used (bodily
pain, mental health, vitality, and physical function), the
questionnaire answers were transformed into a 0–100
range, as per guidelines (29), but were not normed for age
or sex (since both would be adjusted for during analysis).
Each raw subscale is included in its unaltered form, and
this was also used to calculate the percentage changes
between baseline and 1 year. Missing values for vitality
and mental health were replaced with the mean response
if sufﬁcient questions were answered (29). Answers from
both version 1 and version 2 of the SF-36 questionnaire
were included, and subscale calculations were modiﬁed
where necessary. Cases with any missing data for the
bodily pain outcome variable were excluded (n  26 at
baseline). Because thresholds for pain scores are difﬁcult
to establish and interpret, the percentage change in bodily
pain score from baseline to 1 year was calculated for lon-
gitudinal analyses. Participants with less improvement
were deﬁned as those with below median pain change.
DAS28 and DAS28-P index. The DAS28 score was cal-
culated using the ESR and according to standard formulae
(8). Additionally, for patients with active disease (DAS28
3.2), the fraction of the total DAS28 score contributed by
patient-reported components (TJC and patient global as-
sessment) was calculated and is referred to as the DAS28-P
index. Those with a DAS28 3.2 did not have the
DAS28-P index calculated in order to reduce the variation
derived from calculations with small denominators
(DAS28-P index calculated for n 826 at baseline and n
476 at 1 year; see Supplementary Appendix A, available in
the online version of this article at http://onlinelibrary.
wiley.com/journal/10.1002/(ISSN)2151-4658).
The DAS28-P index is calculated as follows:
(0.56TJC) (0.014 GH)
(0.28SJC) (0.56TJC) (0.7 ln(ESR)) (0.014 GH)
Statistical analysis. The measures associated with the
DAS28-P index were analyzed using Spearman’s correla-
tions and Mann-Whitney U tests, with multiple regression
being used to adjust for confounding. Conﬁrmatory sec-
ondary analyses of selected 1-year data were performed
using Wilcoxon’s paired tests.
For measures associated with pain and pain changes,
medians and IQRs or percentages are shown throughout.
DAS28 scores were classiﬁed into European League
Against Rheumatism activity groups (where 0–3.19  in-
active, 3.2–5.19  active, and 5.2  severe) (33), body
mass index (BMI) was classiﬁed into World Health Orga-
nization groups (where 25 kg/m2  normal, 25–29.9
kg/m2  overweight, and 30 kg/m2  obese) (34), and
other continuous variables were split into tertiles of in-
creasing severity or magnitude. Odds ratios and 95% con-
ﬁdence intervals (95% CIs) were calculated initially with-
out adjustment and compared to the least severe reference
group/tertile.
Logistic regression analyses were performed to assess
associations with greater than median bodily pain or less
than median change in bodily pain at 1 year (less im-
provement). Data on nonsteroidal antiinﬂammatory drug
(NSAID), disease-modifying antirheumatic drug (DMARD),
and regular corticosteroid usage were included in the
models to address possible confounding by treatment of
inﬂammatory disease. Secondary analyses with smaller
numbers of baseline variables and using the absolute pain
score at 1 year were undertaken to test the robustness of
ﬁndings from full logistic regression models. Statistical
analysis was performed using SPSS, version 14 (IBM).
Statistical signiﬁcance was taken to be P values less than
0.05 and when 95% CIs did not encompass unity.
RESULTS
Demographics. Of the 1,189 patients recruited to the
database by the time of the study, 977 and 609 had SF-36
bodily pain scores available for baseline and 1 year, re-
spectively. The demographic characteristics of the study
population and the study groups are shown in Table 1, and
the characteristics of those with SF-36 data available were
similar to the entire study population. As previously pub-
lished, the majority of patients in the ERAN received
DMARD monotherapy during the ﬁrst year (25), and in our
subset we found that 56% received methotrexate and 40%
received sulfasalazine as part of their treatment regimens
at the 1-year time point.
DAS28-P index. The baseline median DAS28-P index
was 0.43 (IQR 0.36–0.49). The DAS28-P was positively
correlated with the DAS28, but less so than the individ-
ual components from which both scores were derived




score (n  977)
1-year SF-36
score (n  609)
Age, median (IQR) years 58 (47–68) 58 (48–67) 58 (48–67)
BMI, median (IQR) kg/m2 26.8 (23.9–30.3) 26.8 (23.9–30.3) 26.9 (24.1–30.2)
Women, % (no./total) 68 (805/1,189) 68 (660/977) 66 (404/609)
White, % (no./total) 94 (1,116/1,188) 97 (947/977) 98 (594/609)
Current smoker, % (no./total) 33 (388/1,166) 34 (327/975) 31 (191/608)
* The demographic characteristics of the Early Rheumatoid Arthritis Network (ERAN) study population and
those with Short Form 36 (SF-36) data available were statistically similar. IQR  interquartile range; BMI  body
mass index.
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(Table 2). In order to determine the possible clinical rele-
vance of the DAS28-P index, associations with other char-
acteristics related to the patient experience of disease were
investigated. At baseline, the DAS28-P index was associ-
ated with worse bodily pain scores (r  0.31, P  0.001),
higher DAS28 (r  0.34, P  0.001), greater disability
measured by the HAQ (r  0.28, P  0.001), and younger
age (r  0.22, P  0.001). Baseline scores on the SF-36
subscales indicating lower vitality (r  0.26, P  0.001)
and physical function (r  0.20, P  0.001) were also
associated with a higher DAS28-P index. Multiple linear
regression was performed to investigate which patient-
based factors were associated with the DAS28-P index at
baseline, while controlling for other confounders. Sub-
scales of the SF-36, HAQ, and DAS28 were included with
symptom duration, serology, 1987 ACR criteria, comor-
bidities, extraarticular disease, smoking history, age, sex,
and BMI as covariates. After adjustment for other vari-
ables, the DAS28-P index was signiﬁcantly associated with
worse bodily pain, higher DAS28 score, and younger age
(0.18, P 0.003;  0.25, P 0.001; and 0.19,
P  0.001, respectively).
The median bodily pain scores improved from 41 (IQR
22–62) at baseline to 51 (IQR 31–74) at the 1-year followup
(Z  7.6, P  0.001). Mean  SD total DAS28 scores also
showed a statistically signiﬁcant improvement from base-
line (4.8  1.6) to 1 year (3.8  1.6; t  14.3, P  0.001).
The association between higher DAS28-P index and
greater bodily pain was retained at both time points (base-
line: r  0.31, P  0.001; 1 year: r  0.45, P  0.001).
The DAS28-P, calculated for those with active disease, was
similar at 1 year (median 0.45, IQR 0.35–0.52) and at
baseline (median 0.43, IQR 0.36–0.49; Z  0.62, P 
0.534), despite a signiﬁcant decrease in the total DAS28
between baseline (median 5.6, IQR 4.6–6.3) and 1 year
(median 4.7, IQR 4.0–5.6) in this subgroup (P  0.001).
Baseline associations with pain. When baseline only
was considered, logistic regression analysis revealed that
several covariates were associated with baseline pain score
(Table 3). Worse pain at baseline was observed in men and
those patients with shorter disease duration, high DAS28,
high DAS28-P index, SF-36 scores indicating poorer men-
tal health, and previous smoking.
Predictors of less improvement in pain after 1 year.
The change in pain scores at 1 year was expressed as a
percentage change from baseline, with a median improve-
ment of 19.3% (IQR 16.0% to 80.5%; P  0.001 versus
baseline). Most patients with early RA reported incom-
plete improvement in bodily pain after 1 year (58%), with
the remainder reporting bodily pain scores that were either
the same as (15%) or worse than (27%) baseline. Statisti-
cally signiﬁcant univariate associations with less pain im-
provement at 1 year were seen for female sex, not fulﬁlling
the 1987 ACR criteria, seronegativity, lower bodily pain,
better mental health, and lower disease activity at baseline
(Table 4).
Logistic regression analysis was performed to determine
independent predictors of less improvement in pain at 1
year. Sixteen demographic and clinical covariates were
included in the logistic regression model and are shown in
Table 4. Baseline bodily pain was included to control for
the regression to the mean. After adjustment, a high
DAS28-P index at baseline was associated with less im-
provement in pain after 1 year (Table 4). Among the other
variables, only female sex and low baseline bodily pain
scores were associated with less improvement in pain.
Inclusion of methotrexate or sulfasalazine use at 1 year in
the analysis did not alter the ﬁndings from logistic regres-
sion analysis. Additionally, a smaller logistic regression
model that examined only the DAS28-P and baseline pain
also indicated that a high baseline DAS28-P predicted less
improvement in bodily pain at 1 year (see Supplementary
Appendix B, available in the online version of this article
at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)
2151-4658). Additionally, exclusion of the DAS28 from
our model did not substantially alter the signiﬁcant asso-
ciation between the DAS28-P and less improvement in
pain (data not shown). Further analysis showed that 1-year
pain levels (rather than pain change) were also associated
with the baseline DAS28-P after adjustments for baseline
pain and other covariates (see Supplementary Appendix
B, available in the online version of this article at http://
onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658).
Additional secondary analysis of 1-year cross-sectional
data showed, in contrast to the ﬁndings at baseline, that
female sex was associated with greater pain (Z2.6, P
0.009). Inclusion of NSAID use at baseline into our logistic
regression model for pain change did not show a signiﬁ-
cant association and did not alter the main ﬁndings for
other covariates.
DISCUSSION
Pain is a difﬁcult symptom to measure because it ﬂuctu-
ates and may be experienced or described differently by
different people at different times. Over 1 year after pre-
sentation with RA, as in other studies, we found that pain
levels improved, but also that pain persisted rather than
completely resolved (16,35). Logistic regression analysis
found that lower baseline pain, female sex, and a high
baseline DAS28-P index were associated with less pain
improvement at 1 year, whereas many factors were inde-
pendently associated with pain at baseline. The predictive
Table 2. Relationships between the DAS28 and its






VAS GH 0.66 (0.63–0.70)
* Spearman’s correlation coefﬁcients (95% conﬁdence intervals)
with the Disease Activity Score in 28 joints (DAS28) show the
proportion of the DAS28 attributable to patient-reported compo-
nents (DAS28-P) and individual components of the DAS28. The
DAS28-P shows less dependence upon the DAS28 than the indi-
vidual components. P  0.01 for all components. TJC  tender joint
count; SJC  swollen joint count; ESR  erythrocyte sedimentation
rate; VAS  visual analog scale; GH  general health.
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value of the DAS28-P index may indicate that noninﬂam-
matory mechanisms contribute to the persistence of pain
during the ﬁrst year when the inﬂammatory component of
the disease is treated.
The DAS28 is a validated measure of inﬂammatory dis-
ease activity in RA, although high DAS28 scores may
sometimes be associated with central sensitization rather
than active inﬂammation. Individual DAS28 components
each increase with growing disease activity, whereas dis-
proportionate increases in patient-reported components
may be an indication of noninﬂammatory pain mecha-
nisms. We calculated the DAS28-P index based on the
Table 3. Baseline associations of pain and classic risk factors for RA severity*
Covariate and
tertiles/groups
Unadjusted analyses Logistic regression
OR (95% CI) P ORadj (95% CI) P
Sex 0.43 (0.25–0.74)† 0.003†
Male 1
Female 0.80 (0.60–1.05) 0.108
Age 0.81 (0.59–1.12) 0.206
Tertile 1 1
Tertile 2 1.09 (0.80–1.49) 0.632
Tertile 3 1.00 (0.73–1.38)  0.99
BMI 1.02 (0.75–1.40) 0.887
Normal 1
Overweight 1.33 (0.97–1.83) 0.080
Obese 1.31 (0.92–1.86) 0.155
Smoking history 1.90 (1.17–3.08)† 0.009†
Never smoked 1
Ever smoked 1.62 (1.25–2.12)  0.001
Disease duration 0.64 (0.48–0.86)† 0.003†
Tertile 1 1
Tertile 2 0.64 (0.46–0.89) 0.008
Tertile 3 0.67 (0.48–0.93) 0.018
Seropositivity 1.03 (0.61–1.74) 0.926
Negative 1
Positive 1.06 (0.80–1.41) 0.717
DAS28 3.61 (2.15–6.07)†  0.001†
3.2 1
3.2–5.19 3.46 (2.24–5.36)  0.001
5.2 15.06 (9.31–24.36)  0.001
1987 ACR criteria 1.59 (0.91–2.77) 0.103
4 criteria 1
4 criteria 2.60 (1.99–3.38)  0.001
Extraarticular disease 0.79 (0.42–1.50) 0.478
No 1
Yes 1.21 (0.85–1.73) 0.322
Erosions 0.92 (0.55–1.55) 0.921
None 1
Yes 0.97 (0.73–1.30) 0.881
DAS28-P index 1.42 (1.04–1.93)† 0.026†
Tertile 1 1
Tertile 2 2.35 (1.61–3.44)  0.001
Tertile 3 4.57 (3.00–6.95)  0.001
Comorbidities 1.55 (0.94–2.54) 0.086
0 1
1 1.49 (1.14–1.93) 0.003
SF-36 mental health 2.67 (1.96–3.65)†  0.001†
Tertile 1 1
Tertile 2 3.09 (2.24–4.27)  0.001
Tertile 3 7.89 (5.51–11.31)  0.001
* Unadjusted odds ratios (ORs) and adjusted ORs (ORadj) with 95% conﬁdence intervals (95% CIs) show associations at baseline between bodily pain
(classiﬁed as worse or better than median bodily pain score) and classic risk factors for rheumatoid arthritis (RA) severity (n  368). After adjustment,
worse pain at baseline was associated with male sex, previous smoking, shorter disease duration, more disease activity, higher proportion of the
Disease Activity Score in 28 joints (DAS28) attributable to patient-reported components (DAS28-P), and worse mental health. DAS28 groups, as
classiﬁed by the European League Against Rheumatism, were 0–3.19 (inactive), 3.2–5.19 (active), and5.2 (severe), and body mass index (BMI) groups
were 25 kg/m2 (normal), 25–29.9 kg/m2 (overweight), and 30 kg/m2 (obese; derived from World Health Organization guidelines). Other continuous
data were divided into tertiles of increasing severity for analysis. ACR  American College of Rheumatology; SF-36  Short Form 36.
† Statistically signiﬁcant data after adjustment (P  0.05).
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Table 4. Predictors of less improvement in bodily pain after 1 year*
Covariate and
tertiles/groups
Unadjusted analyses Logistic regression
OR (95% CI) P ORadj (95% CI) P
Sex 3.41 (1.35–8.64)† 0.010†
Male 1
Female 1.62 (1.03–2.53) 0.041
Age 1.42 (0.84–2.39) 0.189
Tertile 1 1
Tertile 2 1.26 (0.76–2.09) 0.367
Tertile 3 1.00 (0.60–1.65)  0.99
BMI 1.63 (0.99–2.70) 0.055
Normal 1
Overweight 0.79 (0.47–1.31) 0.369
Obese 1.02 (0.58–1.79)  0.99
Smoking history 0.99 (0.49–2.06) 0.999
Never smoked 1
Ever smoked 1.03 (0.68–1.57) 0.915
Disease duration 1.02 (0.64–1.63) 0.925
Tertile 1 1
Tertile 2 1.19 (0.71–2.00) 0.513
Tertile 3 1.13 (0.67–1.93) 0.684
Seropositivity 0.61 (0.26–1.42) 0.250
Negative 1
Positive 0.56 (0.35–0.89) 0.017
DAS28 0.60 (0.27–1.34) 0.208
3.2 1
3.2–5.19 0.28 (0.13–0.58)  0.001
5.2 0.14 (0.06–0.29)  0.001
1987 ACR criteria 1.48 (0.64–3.42) 0.359
4 criteria 1
4 criteria 0.44 (0.29–0.68)  0.001
Extraarticular disease 0.95 (0.36–2.52) 0.918
Normal 1
Yes 0.75 (0.44–1.30) 0.334
Erosions 0.95 (0.41–2.22) 0.901
None 1
Yes 0.70 (0.43–1.12) 0.138
DAS28-P index 2.09 (1.24–3.55)† 0.006†
Tertile 1 1
Tertile 2 1.53 (0.86–2.70) 0.153
Tertile 3 1.38 (0.74–2.59) 0.340
SF-36 bodily pain 0.20 (0.10–0.38)†  0.001†
Tertile 1 1
Tertile 2 0.13 (0.07–0.23)  0.001
Tertile 3 0.05 (0.02–0.10)  0.001
SF-36 mental health 1.08 (0.67–1.75) 0.755
Tertile 1 1
Tertile 2 0.57 (0.35–0.94) 0.033
Tertile 3 0.34 (0.20–0.58)  0.001
Comorbidities 1.23 (0.56–2.68) 0.606
0 1
1 1.27 (0.83–1.93) 0.286
Steroids at 1 year 0.87 (0.32–2.35) 0.782
No 1
Yes 0.85 (0.51–1.42) 0.607
MTX at 1 year 0.71 (0.33–1.49) 0.359
No 1
Yes 0.71 (0.47–1.08) 0.136
* Unadjusted odds ratios (ORs) and adjusted ORs (ORadj) with 95% conﬁdence intervals (95% CIs) show associations with less improvement in pain.
Unadjusted ORs for pain are shown in comparison to the least severe or smallest reference group/tertile. The logistic regression model for less
improvement in bodily pain score at 1 year analyzed the risks for below median change (n  184) and compared risk increases per group/tertile. After
adjustments, less improvement in pain was associated with female sex, less pain at baseline, and a higher Disease Activity Score in 28 joints (DAS28)
attributable to patient-reported components (DAS28-P) index. Covariates represent baseline characteristics, except that medications (methotrexate
[MTX] or sulfasalazine and steroids) at 1 year were included to address possible confounding by treatment of inﬂammatory disease. DAS28 groups,
as classiﬁed by the European League Against Rheumatism, were 0–3.19 (inactive), 3.2–5.19 (active), and 5.2 (severe), and body mass index (BMI)
groups were 25 kg/m2 (normal), 25–29.9 kg/m2 (overweight), and 30 kg/m2 (obese; derived from World Health Organization guidelines). Other
continuous data were divided for analysis into tertiles with increasing magnitude or severity. Similar ﬁndings were obtained with another model where
MTX was replaced with sulfasalazine at 1 year. ACR  American College of Rheumatology; SF-36  Short Form 36.
† Statistically signiﬁcant data after adjustment (P  0.05).
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proportion of the DAS28 that was attributable to the pa-
tient’s reported joint tenderness and disease activity.
The DAS28-P index displayed validity as a measure of
the patient’s experience of RA, extending the information
provided by the total DAS28. High DAS28-P indices were
associated with worse pain both at baseline and at 1-year
followup, consistent with a high contribution of pain to
patients’ self-reported disease activity and TJCs. The
DAS28-P index displayed greater statistical independence
from the total DAS28 score than did individual DAS28
components, and the DAS28-P index did not change sig-
niﬁcantly over 1 year in those whose RA remained active,
despite improvements in the total DAS28 (24) and bodily
pain scores. The DAS28-P acted independently of baseline
bodily pain scores and the total DAS28 as a predictor of
less pain improvement at 1 year. Whereas a high DAS28
indicates inﬂammatory disease activity, a high DAS28-P
may suggest noninﬂammatory pain mechanisms.
Together our data indicate that the DAS28-P index rep-
resents a stable characteristic that is distinct from inﬂam-
matory disease activity in patients with continuing active
disease despite conventional therapy. Factors that lead to
a higher DAS28-P index appear to function before the end
of the ﬁrst year of RA symptoms, and a high DAS28-P
index may be present at baseline and is not related to
symptom duration. However, further studies would be
required to determine whether the DAS28-P remains sta-
ble over longer time periods, and whether it may change in
response to non-DMARD interventions.
The DAS28 is commonly used to inform treatment de-
cisions, and health services such as those in the UK may
restrict funding for biologic agents to patients with high
DAS28 scores. Our data indicate that high DAS28 scores
may group together patients with different disease pheno-
types, and that the relative contributions made by the
different DAS28 components have prognostic signiﬁcance.
A better understanding of the contributions of DAS28
components to treatment outcomes has the potential to
enhance the equitable use of disease activity scores in
treatment allocation.
Furthermore, factors that contribute to high DAS28-P
indices may be targets for intervention in early RA, com-
plementing treatments that focus on the inﬂammatory
component of the disease. However, the DAS28-P may
have limited utility in people with inactive DAS28 scores
(3.2), where small denominators used in its calculation
would lead to high measurement error. Further research
would be required to determine whether the DAS28-P has
validity and utility in making treatment decisions.
Less intense disease-modifying treatments are some-
times offered to those people with early RA who have
relatively few observed signs of inﬂammation (36). How-
ever, the DAS28-P index predicted poor pain outcome
even when DMARD choice was included in the regression
model. We hypothesize that high DAS28-P indices may
identify patients with noninﬂammatory mechanisms un-
derlying their pain, for whom treatments that are only
directed at inﬂammation may lead to inadequate pain im-
provement. Other research tools not available in the cur-
rent cohort, such as quantitative sensory testing, may help
elucidate whether the DAS28-P is indeed an index of
sensitization in RA.
Higher self-reported pain in RA has previously been
found in women (37), and we found that women showed
less improvement, although they also had less pain at
baseline. This is consistent with at least 1 other study of
early RA (15). These ﬁndings may indicate differences
between men and women in the progression of pain during
the ﬁrst year of RA, although signiﬁcant sex differences in
pain changes were only demonstrated after adjustment for
confounders.
People with worse baseline scores have greater potential
to improve, and worse baseline pain scores predicted
greater pain improvement at 1 year. The DAS28-P index
also had predictive value. Logistic regression analyses ad-
justed for baseline pain score, indicating that for a given
pain score, a higher DAS28-P index predicted less im-
provement in pain at 1 year. Sensitivity analyses demon-
strated an association between the DAS28-P and less pain
improvement, irrespective of sex or other variables in the
logistic regression analysis.
The SF-36 bodily pain score addresses the overall expe-
rience of pain. Non-RA pain, for example, that arises from
comorbidities, may inﬂuence responses to the bodily pain
questions. High depression indices have been associated
with greater pain in other studies of RA (38), and we found
that bodily pain at baseline was associated with worse
mental health scores. However, baseline mental health
scores did not predict pain outcomes, suggesting that poor
mental health may not be the predominant factor mediat-
ing pain or may be adequately managed in usual care.
Osteoarthritis may be a confounder for pain and tender-
ness, and would be expected to persist despite the sup-
pression of inﬂammatory disease. A more detailed analysis
of comorbidities would be required in order to fully eval-
uate their contributions to pain prognosis in early RA, and
this was beyond the scope of this study. Medication was
not strongly associated with improvement in pain. More
intense treatment including methotrexate may be used for
patients with more painful disease, but may also reduce
symptoms, thereby obscuring associations between medi-
cation use and pain. Different methods than ours may be
more appropriate to determine the course of bodily pain in
relation to medication usage.
People with high DAS28-P indices report more pain,
more disability, and less vitality, characteristics that dis-
play similarities to people with ﬁbromyalgia, where sen-
sitization, TJCs, and global disease assessments are also
high (9). A recent study found that 7–8% of patients with
established RA satisﬁed criteria for ﬁbromyalgia (13). Fi-
bromyalgia may therefore also be viewed as a comorbidity
that could predict pain outcomes. Although data were not
available to classify ﬁbromyalgia within the ERAN cohort,
it is likely that a high DAS28-P index and ﬁbromyalgia
represent related constructs (9). Whereas a diagnosis of
ﬁbromyalgia implies a discrete diagnostic entity, our use
of the DAS28-P index is consistent with a continuous
phenotypic spectrum. Movement of individuals along that
spectrum may explain why patients with RA often satis-
ﬁed criteria for ﬁbromyalgia intermittently, with almost
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20% of patients with established RA fulﬁlling ﬁbromyalgia
criteria at some time during followup (13).
Some other limitations exist in our study. In the absence
of any reference group, it is not possible to determine
whether our ﬁndings are speciﬁc for RA or may be repre-
sentative of the early stages of other chronic painful con-
ditions. The ERAN recorded the onset and diagnostic
codes of comorbidities, but not their severity of treatment.
Data were excluded from a proportion of patients that had
not ﬁlled in the SF-36 questionnaire, although the demo-
graphics of the groups analyzed remained representative
of the study population. The clinical importance of the
change in pain level is difﬁcult to evaluate. In our logistic
regression models we used the median improvement in
pain of approximately 20% as the cutoff between more or
less improvement. Small changes in pain scores may not
have clinical importance for people with musculoskeletal
conditions (39), and further research would be required to
determine whether our “less improved” group includes
people with clinically important deterioration in pain who
may beneﬁt from different treatments aimed at preventing
pain deterioration.
In summary, the factors most likely to be related to
poorer pain outcomes in early RA are female sex and a
high baseline DAS28-P index. Noninﬂammatory factors
such as central sensitization may contribute to poor pain
prognosis in early RA. The DAS28-P index may provide an
index of noninﬂammatory pain for epidemiologic studies
in RA, and warrants further validation studies.
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